Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of perennial allergic rhinitis.~* Age \>= 6 years old and \<= 12 years old.~* Patients in good general conditions, without any other relevant clinical condition except for perennial allergic rhinitis.~* Symptoms total score at admission \>= 8 (out of 15 possible). Individual symptoms (score 0 to 3 points) were: Sneezing or nasal pruritus, eye reddening or pruritus, nasal congestion, wet nose or with secretion (sniffing), secretion sensation at pharynx (post-nasal dripping).~* Number of symptoms: At least three.~Exclusion Criteria:~* Age \< 6 years old or \> 12 years old.~* Co-existence of acute sinusitis or some chronic condition different from asthma or atopic dermatitis.~* Presence of systemic fungal infections.~* Conscience or behavioral disturbances.~* Current oral or parenteral steroid treatment.~* Concomitant use of Phenobarbital, rifampicin, diphenylhydantoin or ephedrine.~* Known hypersensitivity to any of the study pharmacological combination components.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- loratadine/betamethasone oral solution (Type: EXPERIMENTAL): loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).